Strategies for managing cytomegalovirus in transplant recipients

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.

Original languageEnglish (US)
Pages (from-to)1983-1997
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number12
DOIs
StatePublished - 2010

Fingerprint

Cytomegalovirus
Allografts
Disease Resistance
Transplant Recipients
Cytomegalovirus Infections
Organ Transplantation
Antiviral Agents
Transplantation
Guidelines
Transplants
Survival
Incidence
Therapeutics

Keywords

  • Cytomegalovirus
  • Outcome
  • Preemptive therapy
  • Prophylaxis
  • Transplantation
  • Valganciclovir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Strategies for managing cytomegalovirus in transplant recipients. / Razonable, Raymund R.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 12, 2010, p. 1983-1997.

Research output: Contribution to journalArticle

@article{5ae41fdfa33a48d792291636def9d67d,
title = "Strategies for managing cytomegalovirus in transplant recipients",
abstract = "Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.",
keywords = "Cytomegalovirus, Outcome, Preemptive therapy, Prophylaxis, Transplantation, Valganciclovir",
author = "Razonable, {Raymund R}",
year = "2010",
doi = "10.1517/14656566.2010.492395",
language = "English (US)",
volume = "11",
pages = "1983--1997",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Strategies for managing cytomegalovirus in transplant recipients

AU - Razonable, Raymund R

PY - 2010

Y1 - 2010

N2 - Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.

AB - Importance of the field: Cytomegalovirus (CMV) is the most important pathogen that affects transplant recipients, by directly causing clinical disease and by indirectly reducing patient and allograft survival. Areas covered in this review: This review provides a brief overview of the direct and indirect effects of CMV disease and the traditional and newly described factors that increase the risk of disease after transplantation. Newly acquired data in the diagnostics, prevention and treatment of CMV infection are discussed, with emphasis on guidelines for management as recently endorsed by the American Society of Transplantation and the Transplantation Society. What the reader will gain: The reader will gain up-to-date insights into the contemporary management of CMV after solid organ transplantation. Practical aspects of its diagnosis, prevention and treatment are discussed. Emerging concerns of late-onset CMV disease and antiviral resistance are also highlighted to emphasize the need to optimize CMV-prevention strategies. Take home message: Prevention of CMV disease is an important goal in the management of solid organ transplant recipients. The efficacy of CMV prevention should be measured not only by the significant reduction in CMV incidence but, as importantly, by the improvement in long-term allograft and patient survival.

KW - Cytomegalovirus

KW - Outcome

KW - Preemptive therapy

KW - Prophylaxis

KW - Transplantation

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=77954813558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954813558&partnerID=8YFLogxK

U2 - 10.1517/14656566.2010.492395

DO - 10.1517/14656566.2010.492395

M3 - Article

C2 - 20642369

AN - SCOPUS:77954813558

VL - 11

SP - 1983

EP - 1997

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -